ClinicalTrials.gg
CompletedNCT06268860Updated Oct 23, 2026Results posted

A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants

A Phase 1 interventional study of Rocatinlimab vial injection and Rocatinlimab prefilled syringe in Atopic Dermatitis, sponsored by Amgen. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

How we know

Updated Oct 23, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing KHK4083 in Dermatitis, Atopic — none open to participants now, none under way, none of them phase 3. KHK4083 · Dermatitis, Atopic.

Enrollment
7th of 14
240 · median 236
Started
2024
with 3 others
Phase 1
5 of 14
none open now
Registered
13th of 14
by date
Lead sponsor
12 of 14
Amgen

Among the 14 studies testing KHK4083 in Dermatitis, Atopic, this one is the 7th largest by enrollment, is one of 4 that started in 2024, is one of 5 in phase 1, and was the 13th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 14 studies testing KHK4083 in Dermatitis, Atopic is open now. The open studies under Dermatitis, Atopic, anywhere →

About KHK4083

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing KHK4083 in Dermatitis, Atopic as a file.
02

Study summary

The primary objective of the study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) dose in a vial compared to a prefilled syringe in healthy participants.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Rocatinlimab
  • AMG 451
  • Dermatology
  • Pharmacokinetics
  • Safety
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has provided before initiation of any study-specific activities/procedures.
  2. Healthy male or female participants, between 18 and 65 years of age (inclusive)
  3. between 18 and 32 kg/m\^2 (inclusive)

Exclusion criteria

Exclusion Criteria

  1. History or evidence, at Screening or Check-in, of disorder, condition, or disease not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
  2. History or evidence of clinically significant arrhythmia at Screening, including any clinically significant findings on the (ECG) taken at Check-in.
  3. A corrected for heart rate using Fridericia's method (QTcF) > 450 msec in male participants or > 470 msec in female participants or history/evidence of long QT syndrome at Screening or Check-in.
  4. Systolic blood pressure > 140 mmHg or \< 90 mmHg, or diastolic blood pressure > 90 mmHg, or pulse rate > 100 bpm
  5. History of , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee). Participants with seasonal allergies will be permitted.
  6. Estimated less than 70 mL/min/1.73 m\^2
  7. or aspartate aminotransferase > 1.5 times the at Screening or Check-in.
  8. Positive or panel (including positive hepatitis B surface antigen [HBsAg] and/or positive hepatitis C antibody) and/or positive test at Screening. Participants whose results are compatible with prior hepatitis B vaccination (positive hepatitis B surface antibody, negative hepatitis B core antibody, negative HBsAg) or prior infection (positive hepatitis B core antibody, positive hepatitis B surface antibody, negative HBsAg) may be included.
  9. Participants who have received within 5 weeks prior to Screening, or plan to receive live vaccines within 90 days after administration of an product.

    Inactive vaccination (e.g., non-live or nonreplicating agent), including coronavirus-2019 (COVID-19) vaccination, is allowed.

  10. History of latent tuberculosis or active chronic, recurrent, or acute infection requiring treatment with systemic antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungals which has not completely resolved, or for which therapy has not been completed, within 4 weeks before Screening.
  11. Use of any over-the-counter or prescription medications within 30 days or 5 half-lives (whichever is longer) before Check-in, excluding the following:

    1. Acetaminophen (paracetamol) (up to 2 g per day) for analgesia will be allowed.
    2. Hormonal listed in Appendix 3 will be allowed.
    3. Hormone replacement therapy (e.g., estrogen) and hormonal contraceptives will be allowed.
  12. All herbal medicines (e.g., St. John's wort), vitamins, and supplements consumed by the participant within the 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee) and in consultation with the Sponsor.
  13. Participant has received a dose of an investigational drug within the past 90 days or 5 half-lives, whichever is longer, prior to Check-in.
  14. Have previously completed or withdrawn from this study or any other study investigating rocatinlimab or have previously received rocatinlimab.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Rocatinlimab Vial

    Participants will receive rocatinlimab vial solution SC

    Drug: Rocatinlimab vial injection

  • Experimental
    Rocatinlimab Prefilled Syringe

    Participants will receive rocatinlimab prefilled syringe solution SC

    Combination Product: Rocatinlimab prefilled syringe

Interventions

  • DrugKHK4083Studies of KHK4083KHK4083 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Vial solution for SC injection administered on Day 1

    Also known as: AMG 451

  • Combination productKHK4083Studies of KHK4083KHK4083 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Prefilled syringe solution for SC injection administered on Day 1

    Also known as: AMG 451

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of Rocatinlimab

    Pharmacokinetic (PK) parameters were determined from the serum concentrations of rocatinlimab using noncompartmental methods in a validated software program.

    Time frame: At predose on Day 1 and postdose on Day 1 through Day 112

  2. Area Under the Serum Concentration-time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rocatinlimab

    PK parameters were determined from the serum concentrations of rocatinlimab using noncompartmental methods in a validated software program.

    Time frame: At predose on Day 1 and postdose on Days 1 through Day 112

  3. AUC From Time Zero to Infinity (AUCinf) of Rocatinlimab

    PK parameters were determined from the serum concentrations of rocatinlimab using noncompartmental methods in a validated software program.

    Time frame: At predose on Day 1 and postdose on Days 1 through Day 112

Secondary outcomes

  1. Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAE)

    An AE was any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the study treatment. A TEAE was defined as an AE that started during or after the dosing of trial treatment and up to the end of trial (EOT).

    Time frame: From first dose of trial drug until the end of trial; median (min, max) duration on trial was 16.0 (1.0, 20.3) weeks

  2. Number of Participants Who Experienced Serious AEs (SAE)

    An \[JS12.1\]\[MS12.2\]AE was any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the study treatment. A SAE was defined as any AE that resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital abnormality or birth defect or important medical events that did not meet the preceding criteria but based on appropriate medical judgment could jeopardize the participant or could require medical or surgical intervention to prevent any of the outcomes listed.

    Time frame: From first dose of trial drug until the end of trial; median (min, max) duration on trial was 16.0 (1.0, 20.3) weeks

  3. Number of Participants Positive to Anti-rocatinlimab Antibody

    Blood samples were collected for anti-rocatinlimab antibody testing. The following results are reported: * Participant with positive result at baseline; * Participant with treatment-boosted antibody (the number of participants who were binding antibody positive at baseline and with an increase in titer greater than or equal to 4-fold from baseline); * Participant with treatment-induced antibody positive result (are participants who were antibody-negative or had missing data at baseline but developed an antibody response after dosing); * Participant with treatment-emergent antibody incidence (the sum of participants with treatment-boosted or treatment-induced antibody responses); * Participant with treatment-induced neutralizing antibody positive result.

    Time frame: At predose on Day 1 and Days 28, 56 and 112

07

Results

Posted Oct 23, 2026

Participant flow

A total of 240 participants were enrolled from February to October 2024.

Participant flow — Overall Study
MilestoneTreatment A: Rocatinlimab 300 mg/2 mL VialTreatment B: Rocatinlimab 300 mg/2 mL Prefilled Syringe
Started120120
Completed114111
Not completed69
Withdrew: Withdrawal by subject24
Withdrew: Lost to follow-up31
Withdrew: Behavior issues10
Withdrew: Adverse event01
Withdrew: Family emergency01
Withdrew: Investigator decision02

Outcome measures

PrimaryMaximum Observed Serum Concentration (Cmax) of Rocatinlimab

Pharmacokinetic (PK) parameters were determined from the serum concentrations of rocatinlimab using noncompartmental methods in a validated software program.

Time frame:
At predose on Day 1 and postdose on Day 1 through Day 112
Reported as:
Geometric mean · μg/mL
Maximum Observed Serum Concentration (Cmax) of Rocatinlimab
μg/mLTreatment A: Rocatinlimab 300 mg/2 mL VialTreatment B: Rocatinlimab 300 mg/2 mL Prefilled Syringe
Maximum Observed Serum Concentration (Cmax) of Rocatinlimab36.3 ± 35.836.0 ± 38.6
PrimaryArea Under the Serum Concentration-time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rocatinlimab

PK parameters were determined from the serum concentrations of rocatinlimab using noncompartmental methods in a validated software program.

Time frame:
At predose on Day 1 and postdose on Days 1 through Day 112
Reported as:
Geometric mean · h*μg/mL
Area Under the Serum Concentration-time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rocatinlimab
h*μg/mLTreatment A: Rocatinlimab 300 mg/2 mL VialTreatment B: Rocatinlimab 300 mg/2 mL Prefilled Syringe
Area Under the Serum Concentration-time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rocatinlimab24800 ± 37.725100 ± 39.5
PrimaryAUC From Time Zero to Infinity (AUCinf) of Rocatinlimab

PK parameters were determined from the serum concentrations of rocatinlimab using noncompartmental methods in a validated software program.

Time frame:
At predose on Day 1 and postdose on Days 1 through Day 112
Reported as:
Geometric mean · h*μg/mL
AUC From Time Zero to Infinity (AUCinf) of Rocatinlimab
h*μg/mLTreatment A: Rocatinlimab 300 mg/2 mL VialTreatment B: Rocatinlimab 300 mg/2 mL Prefilled Syringe
AUC From Time Zero to Infinity (AUCinf) of Rocatinlimab25400 ± 37.125700 ± 39.0
SecondaryNumber of Participants Who Experienced Treatment-emergent Adverse Events (TEAE)

An AE was any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the study treatment. A TEAE was defined as an AE that started during or after the dosing of trial treatment and up to the end of trial (EOT).

Time frame:
From first dose of trial drug until the end of trial; median (min, max) duration on trial was 16.0 (1.0, 20.3) weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAE)
ParticipantsTreatment A: Rocatinlimab 300 mg/2 mL VialTreatment B: Rocatinlimab 300 mg/2 mL Prefilled Syringe
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAE)7068
SecondaryNumber of Participants Who Experienced Serious AEs (SAE)

An \[JS12.1\]\[MS12.2\]AE was any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the study treatment. A SAE was defined as any AE that resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital abnormality or birth defect or important medical events that did not meet the preceding criteria but based on appropriate medical judgment could jeopardize the participant or could require medical or surgical intervention to prevent any of the outcomes listed.

Time frame:
From first dose of trial drug until the end of trial; median (min, max) duration on trial was 16.0 (1.0, 20.3) weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Serious AEs (SAE)
ParticipantsTreatment A: Rocatinlimab 300 mg/2 mL VialTreatment B: Rocatinlimab 300 mg/2 mL Prefilled Syringe
Number of Participants Who Experienced Serious AEs (SAE)11
SecondaryNumber of Participants Positive to Anti-rocatinlimab Antibody

Blood samples were collected for anti-rocatinlimab antibody testing. The following results are reported: * Participant with positive result at baseline; * Participant with treatment-boosted antibody (the number of participants who were binding antibody positive at baseline and with an increase in titer greater than or equal to 4-fold from baseline); * Participant with treatment-induced antibody positive result (are participants who were antibody-negative or had missing data at baseline but developed an antibody response after dosing); * Participant with treatment-emergent antibody incidence (the sum of participants with treatment-boosted or treatment-induced antibody responses); * Participant with treatment-induced neutralizing antibody positive result.

Time frame:
At predose on Day 1 and Days 28, 56 and 112
Reported as:
Count of participants · Participants
Number of Participants Positive to Anti-rocatinlimab Antibody
ParticipantsTreatment A: Rocatinlimab 300 mg/2 mL VialTreatment B: Rocatinlimab 300 mg/2 mL Prefilled Syringe
Positive result at baseline710
Treatment-boosted antibody32
Treatment-induced antibody positive result5052
Treatment-emergent antibody incidence5354
Treatment-induced neutralizing antibody positive result3528

Adverse events

Collected over For mortality reporting, from randomization until the end of trial; median (min, max) time on trail was 16.0 (1.0, 20.3) weeks. For TEAE reporting, from first dose of trial drug until the end of trial; median (min, max) duration on trial was 16.0 (1.0, 20.3) weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: Rocatinlimab 300 mg/2 mL Vial0/120 (0%)1/120 (0.8%)42/120 (35%)
Treatment B: Rocatinlimab 300 mg/2 mL Prefilled Syringe0/120 (0%)1/120 (0.8%)48/120 (40%)
Most frequent serious events
Most frequent serious events
EventTreatment A: Rocatinlimab 300 mg/2 mL VialTreatment B: Rocatinlimab 300 mg/2 mL Prefilled Syringe
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1200/120
Ovarian germ cell teratomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1201/120
Most frequent other events
Most frequent other events
EventTreatment A: Rocatinlimab 300 mg/2 mL VialTreatment B: Rocatinlimab 300 mg/2 mL Prefilled Syringe
HeadacheNervous system disorders33/12036/120
ChillsGeneral disorders13/12018/120
MyalgiaMusculoskeletal and connective tissue disorders12/12015/120
NauseaGastrointestinal disorders10/1208/120
CoughRespiratory, thoracic and mediastinal disorders1/1206/120
Oropharyngeal painRespiratory, thoracic and mediastinal disorders6/1204/120

Baseline characteristics

Safety Population: included all participants who received at least 1 dose of rocatinlimab and had at least 1 postdose safety assessment.

Age, Continuous
Age, Continuous(years)Treatment A: Rocatinlimab 300 mg/2 mL VialTreatment B: Rocatinlimab 300 mg/2 mL Prefilled SyringeTotal
Mean42.2 ± 12.4740.9 ± 11.8941.5 ± 12.18
Sex: Female, Male
Sex: Female, Male(Participants)Treatment A: Rocatinlimab 300 mg/2 mL VialTreatment B: Rocatinlimab 300 mg/2 mL Prefilled SyringeTotal
Female5451105
Male6669135
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment A: Rocatinlimab 300 mg/2 mL VialTreatment B: Rocatinlimab 300 mg/2 mL Prefilled SyringeTotal
Hispanic or Latino363369
Not Hispanic or Latino8487171
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment A: Rocatinlimab 300 mg/2 mL VialTreatment B: Rocatinlimab 300 mg/2 mL Prefilled SyringeTotal
White7564139
Black or African American394382
Asian369
Multiple235
American Indian or Alaska Native022
Other112
Native Hawaiian or Other Pacific Islander011
08

Study locations

4 sites
  • Fortrea Clinical Research Unit - Daytona Beach
    Daytona Beach, Florida 32117-5116, United States
  • Fortrea Clinical Research Unit - Dallas
    Dallas, Texas 75247-4903, United States
  • Fortrea Clinical Research Unit Inc. - Madison
    Madison, Wisconsin 53704-2526, United States
  • Fortrea Clinical Research Unit Limited - Leeds
    Leeds, LDS LS2 9LH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Aug 2024, 6 months.

Results were first posted in Oct 2026, 2 years 1 month after primary completion.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 6 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2024
First posted
Feb 20, 2024
StartActual
Feb 15, 2024
Primary completionActual
Aug 30, 2024
CompletionActual
Oct 8, 2024
Results first posted
Oct 23, 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 23, 2026
Primary outcomes
3 time frame changed, 3 description edited
What changed in the outcomes
  • Time frameMaximum Observed Serum Concentration (Cmax) of RocatinlimabUp to Day 112 → At predose on Day 1 and postdose on Day 1 through Day 112
  • Time frameArea Under the Serum Concentration-time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of RocatinlimabUp to Day 112 → At predose on Day 1 and postdose on Days 1 through Day 112
  • Time frameAUC From Time Zero to Infinity (AUCinf) of RocatinlimabUp to Day 112 → At predose on Day 1 and postdose on Days 1 through Day 112
  • DescriptionAUC From Time Zero to Infinity (AUCinf) of Rocatinlimab: how it is measured was reworded
  • DescriptionArea Under the Serum Concentration-time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rocatinlimab: how it is measured was reworded
  • DescriptionMaximum Observed Serum Concentration (Cmax) of Rocatinlimab: how it is measured was reworded
Oct 23, 2026
Documents
Secondary outcomes
2 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • EditedNumber of Participants ExperiencingWho Experienced Treatment-emergent Adverse Events (TEAE)Time frame: Up to approximately 20 weeks → From first dose of trial drug until the end of trial; median (min, max) duration on trial was 16.0 (1.0, 20.3) weeks
  • EditedNumber of Participants ExperiencingWho Experienced Serious Adverse EventsAEs (SAE)Time frame: Up to approximately 20 weeks → From first dose of trial drug until the end of trial; median (min, max) duration on trial was 16.0 (1.0, 20.3) weeks
  • Time frameNumber of Participants Positive to Anti-rocatinlimab AntibodyUp to Day 112 → At predose on Day 1 and Days 28, 56 and 112
  • DescriptionNumber of Participants Positive to Anti-rocatinlimab Antibody: how it is measured was reworded
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Results posted
    Primary outcomes 3 time frame changed, 3 description edited
    What changed in the outcomes
    • Time frameMaximum Observed Serum Concentration (Cmax) of RocatinlimabUp to Day 112 → At predose on Day 1 and postdose on Day 1 through Day 112
    • Time frameArea Under the Serum Concentration-time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of RocatinlimabUp to Day 112 → At predose on Day 1 and postdose on Days 1 through Day 112
    • Time frameAUC From Time Zero to Infinity (AUCinf) of RocatinlimabUp to Day 112 → At predose on Day 1 and postdose on Days 1 through Day 112
    • DescriptionAUC From Time Zero to Infinity (AUCinf) of Rocatinlimab: how it is measured was reworded
    • DescriptionArea Under the Serum Concentration-time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rocatinlimab: how it is measured was reworded
    • DescriptionMaximum Observed Serum Concentration (Cmax) of Rocatinlimab: how it is measured was reworded
    Secondary outcomes 2 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • EditedNumber of Participants ExperiencingWho Experienced Treatment-emergent Adverse Events (TEAE)Time frame: Up to approximately 20 weeks → From first dose of trial drug until the end of trial; median (min, max) duration on trial was 16.0 (1.0, 20.3) weeks
    • EditedNumber of Participants ExperiencingWho Experienced Serious Adverse EventsAEs (SAE)Time frame: Up to approximately 20 weeks → From first dose of trial drug until the end of trial; median (min, max) duration on trial was 16.0 (1.0, 20.3) weeks
    • Time frameNumber of Participants Positive to Anti-rocatinlimab AntibodyUp to Day 112 → At predose on Day 1 and Days 28, 56 and 112
    • DescriptionNumber of Participants Positive to Anti-rocatinlimab Antibody: how it is measured was reworded
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06268860
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Feb 15, 2024
Primary completion
Aug 30, 2024
Completion
Oct 8, 2024
Results posted
Oct 23, 2026
Last update
Oct 23, 2026

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KHK4083

Start the discussion